1、个人简介

 黄茂华，博士，副研究员，博士生导师。2021年毕业于暨南大学中药药理学专业，获博士学位；同年7月进入暨南大学中西医结合博士后流动站进行博士后研究。2023年6月加入暨南大学药学院，主要围绕肿瘤耐药和转移的发生机制与干预药物发现等方面开展研究工作，近年还关注肿瘤代谢、肿瘤免疫调控等方向。先后主持国家自然科学基金青年基金项目、广东省区域联合基金-重点项目/青年基金项目、广东省自然科学基金-面上项目等国家及省部级项目6项；作为课题核心成员参与国自然重大项目、国家科技重大专项-重大新药创制项目、国自然面上项目、区域联合基金-重点项目等项目10余项。入选广东省科协青年科技人才培育计划。已发表SCI论文30余篇，以第一/通讯作者（含共同）在Nat Metab、Gut、Sci Bull、Drug Resist Updat（2篇）、J Clin Invest、J Extracell Vesicles、J Immunother Cancer等本领域期刊发表SCI论文16篇（其中3篇论文IF≥20，共计10篇论文IF≥10；1篇入选ESI高被引论文）。参编高等学校“十四五”医学规划新形态教材《药理学》（数字课程编委会）、药学“101计划”核心教材《生命药学》等中文著作2部，英文论著1部（Academic Press）。申请中国发明专利4项，获授权中国发明专利1项。

2、讲授课程

      本科生课程：《生物化学》

      研究生课程：《药物筛选新技术》、《中药药效研究思路与方法》、《科研论文写作（药理+临药方向）》、《药物遗传学》

3、研究方向：

      1）肿瘤基质细胞（周细胞、肿瘤相关成纤维细胞、内皮细胞）调控肿瘤进展的机制与靶向药物研究

      2）肿瘤微环境代谢-表观遗传调控肿瘤进展的机制及干预策略研究

4、代表性科研项目：

      [1] 国家自然科学基金青年基金项目（项目编号：82204427, 主持）

      [2] 广东省区域联合基金-重点项目（项目编号：2024B1515120016, 主持）

      [3] 广州市科技计划项目-青年博士启航项目（项目编号：2025A04J3400，主持）

      [4] 广东省自然科学基金-面上项目（项目编号: 2023A1515010361，主持）

      [5] 广东省区域联合基金-青年基金项目（项目编号: 2021A1515110242，主持）

      [6] 中国博士后科学基金面上项目（项目编号: 2022M711345，主持）

5、近5年代表性论文（^#第一作者，^*通讯作者）

[1] Wang S^#, Ye GN^#, Xu XL^#, Lin YN^#, Li XB^#, Zhang Z, Qi M, Tan L, Cheng MJ, Zhang HS, Pan JH,  Lin CW, Huang DD, Deng R,  Li  XM, Wang GS, Qiu SH, Chu XD, Chen YH, Zeng HH, Zhang JQ, Wang CR, Shuai HL, Shi CZ, Yuan X, Cao YH*, Chen MF*, Huang MH*, Ye WC*, Zhang DM*. Pericyte drives the formation of circulating tumor cell-neutrophil clusters to promote colorectal cancer metastasis.Gut, 2025;75(1):81-93.

[2] Sheng Wang^#, Geni Ye^#, Caiyun Zhang^#, Lin Tan, Zhang Zhang, Xi Xu, Xinhui Chen, Yiming Zhang, Xiaoling Xu, Jinghua Pan, Tong Lan, Junqiu Zhang, Changwei Lin, Dandan Huang, Xiaobo Li, Xia Yuan, Minfeng Chen, Chenran Wang*, Wencai Ye*, Dongmei Zhang*, Maohua Huang*. Pericyte NNMT drives an immune-hostile vascular niche and restricts cancer immunotherapy. Sci Bull. 2026; S2095-9273(26)00147-7.

[3] Wang CR^#, Huang MH^#, Lin YN^#, Zhang YM, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat Metab, 2023;5(10):1765-1786.

[4] Huang MH^#, Lin YN^#, Wang CR^#, Deng LJ, Chen MF, Yehuda G. Assaraf, Chen ZS*, Ye WC*, Zhang DM*. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat, 2022;64:100849.

[5] Huang MH^#, Chen MF^#, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Tang P. M-K, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles, 2021;10(7):e12096.

[6] Wen Q^#, Huang MH^#, Xie JW^#, Liu RY^#, Miao Q, Huang JJ, Zhang JQ, Lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS*, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resist Updat, 2023;69:100975.

[7] Qi M^#, Fan SR^#, Huang MH^#, Pan JH, Li Y, Miao Q, Lyu WY, Li XB, Deng LJ, Qiu SH, Liu TZ, Deng WQ, Chu XD, Jiang C, He WZ, Xia LP, Yang YL, Hong J, Qi Q, Yin WQ, Liu XN, Shi CZ, Chen MF*, Ye WC*, Zhang DM*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. J Clin Invest, 2022;132(19):e157399.

[8] Huang MH^#, Liu MQ^#, Huang DD^#, Ma YP, Ye GN, Wen Q, Li Y, Deng LJ, Qi Q, Liu TZ, Liu XN, Chen MF*, Ye WC*, Zhang DM*. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Lett, 2022;524:131-143.

[9] Ye GN^#, Huang MH^#, Li Y, Ouyang J, Chen MF, Wen Q, Li XB, Zeng HH, Long P, Fan ZP, Yin JQ*, Ye WC*, Zhang DM*. The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the Axl pathway. Acta Pharm Sin B, 2022;12(3):1288-1304.

[10] Huang MH^#, Qi M^#, Yang HY^#, Peng Z, Chen SG, Liang MC, Hu YZ*, Deng LJ*, Hu M*. Noninvasive strategies for the treatment of tiny liver cancer: integrating photothermal therapy and multimodality imaging EpCAM-guided nanoparticles. ACS Appl Mater Interfaces, 2023;15(18):21843-21853.

[11] Wang S^#, Huang MH^#, Chen MF^#, Sun ZT^#, Jiao YB, Ye GN, Pan JH, Ye WC*, Zhao JF*, Zhang DM*. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.J Immunother Cancer, 2023;11(6):e006381.

[12] Wang CR^#, Tan L^#, Huang MH^#, Lin YN, Cai MX, Deng LJ, Hu XP, Qiu SH, Chen XT, Zhang YM, Luo XM, Shi CZ, Chen, MF, Ye WC, Zhang JQ*, Zhang DM*, Liu XN*. Cancer ENO2 induces histone lactylation-mediated M2 macrophage polarization and facilitates metastasis of head and neck squamous cell carcinoma. Engineering, 2025;48:262-276.

[13] Ye GN^#, Jiao YB^#, Deng LJ^#, Cheng MJ, Wang S, Ou-yang J, Li Y, He YX, Tu ZC, Wang Z, Song XJ, Wang CR, Qi Q, Zhang DM, Wang L*, Huang MH*, Ye WC*, Chen MF*. Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway.Int J Biol Sci, 2023;19(14):4376-4392.

6、联系方式：

      电子邮箱：Huangmh@jnu.edu.cn

      通讯地址：广州市天河区黄埔大道西601号暨南大学第二理工楼623室、粤港澳中枢神经再生研究院（原老药学院）120室